The historical rank and industry rank for Rosetta Genomics's Gross Margin % or its related term are showing as below:
ROSGQ's Gross Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 50.97 * Ranked among companies with meaningful Gross Margin % only.
Rosetta Genomics had a gross margin of 31.65% for the quarter that ended in Jun. 2017 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Rosetta Genomics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Rosetta Genomics had a gross margin of 31.65% for the quarter that ended in Jun. 2017 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Rosetta Genomics Gross Margin % Related Terms
Rosetta Genomics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Rosetta Genomics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROSGQ vs TEAR, IDTA, ABMC: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Rosetta Genomics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rosetta Genomics Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Rosetta Genomics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Rosetta Genomics (ROSGQ) has a Gross Margin % of 31.65% as of Jun. 2017. Gross margin is the ratio of total gross profit to net sales. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Gross Margin % too high?
Rosetta Genomics' current Gross Margin % is 31.65%. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. Rosetta Genomics' value of 31.65% is 37.9% below this industry median.
How does Rosetta Genomics' Gross Margin % compare to TEAR and IDTA?
Rosetta Genomics' Gross Margin % of 31.65% can be compared against companies in the Medical Diagnostics & Research industry. The industry median Gross Margin % is 50.97. Rosetta Genomics' value of 31.65% is 37.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rosetta Genomics's current Gross Margin % of 31.65% is 37.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Gross Margin % is 31.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Gross Margin % of 31.65%. The current Gross Margin % is 31.65% and 37.9% below the Medical Diagnostics & Research industry median of 50.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Gross Margin % is 31.65% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROSGQ has been successfully added to your 